

Contents lists available at ScienceDirect

Data in Brief

journal homepage: www.elsevier.com/locate/dib

Data Article

# Data describing IFNγ-mediated viral clearance in an adult mouse model of respiratory syncytial virus (RSV)



Katherine M. Eichinger<sup>a,b,c</sup>, Kerry M. Empey<sup>a,b,c,d,\*</sup>

<sup>a</sup> Department of Pharmacy and Therapeutics, Pittsburgh, PA, USA

<sup>b</sup> Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA

<sup>c</sup> Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

<sup>d</sup> Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA

## ARTICLE INFO

Article history: Received 5 June 2017 Received in revised form 5 July 2017 Accepted 13 July 2017 Available online 19 July 2017

Keywords: Immunology Cytokine RSV IFNγ Mice

## ABSTRACT

The data presented here are related to the research article entitled "Age predicts cytokine kinetics and innate immune cell activation following intranasal delivery of IFNγ and GM-CSF in a mouse model of RSV infection" (Eichinger et al., 2017) [1]. The cited manuscript demonstrated that the macrophage-stimulating cytokine, interferon gamma (IFNγ), but not granulocyte macrophage-colony stimulating factor (GM-CSF), effectively enhanced viral clearance in infant mice infected with respiratory syncytial virus (RSV) following intranasal delivery. This article describes the immune response and viral clearing effects of intranasal IFNγ in RSV-infected adult BALB/c mice demonstrating delayed production of endogenous IFNγ. The dataset is made publicly available to extrapolate the role of IFNγ in RSV-infected adult mice.

© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

DOI of original article: http://dx.doi.org/10.1016/j.cyto.2017.05.019

http://dx.doi.org/10.1016/j.dib.2017.07.034

2352-3409/© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

<sup>\*</sup> Correspondence to: 207 Salk Pavilion 335 Sutherland Drive Pittsburgh, PA 15260, USA. Office Tel.: 412-648-9629. *E-mail address:* kme33@pitt.edu (K.M. Empey).

Subject area More specific subject area	Immunology, virology Effects of pulmonary cytokines on infant RSV infection and immunity
Type of data	Text file and graphs
How data was acquired	Flow cytometry (LSR II), Luminex (BioRad)
Data format	Analyzed
Experimental factors	Cytokine levels in the bronchoalveolar lavage fluid, innate and adaptive immune response, daily weights, and viral lung titers were collected to determine the effect of intranasal IFN <sub>γ</sub> in RSV-infected adult mice.
Experimental features	The immune response and viral clearance will be compared in RSV-infected adult mice receiving intranasal IFN $\gamma$ or PBS.
Data source location	Pittsburgh, USA
Data accessibility	The data will be available with this article

# Value of the data

- The data demonstrates that adult mice infected with RSV have delayed IFNγ production and could be used by others developing immunotherapies for RSV disease.
- The data describes innate and adaptive immune responses to locally delivered IFNγ during adult RSV infection which is frequently targeted by RSV vaccine candidates and may inform vaccine strategies.
- Describes the effect of intranasal cytokine delivery on viral clearance in adult mice and allows other researchers to extend this data to further investigations.
- Demonstrates the safety of intranasal IFNγ delivery in RSV-infected adult mice and provides evidence of potential clinical applications with additional studies.




Fig. 1. The percent change in daily weights compared to baseline (A) and viral clearance over time (B) are shown in RSV-infected adult BALB/c mice treated with intranasal IFN $\gamma$  or PBS. A one-way ANOVA indicates significant differences between the groups; \*p < 0.05.





Fig. 2. Cytokine production in the BALF (A-E) of adult BALB/c mice infected with RSV are shown for groups treated with intranasal IFN $\gamma$  or PBS. Mean and SEM are reported with  $\geq$  5 mice per group; a one-way ANOVA describes group differences: \*p < 0.05; \*\*p < 0.01.

## 1. Data

The dataset of this article describes delayed IFNγ production in adult mice infected with RSV as well as the immune response and viral clearing effects of IFNγ when delivered intranasally compared to PBS alone. Fig. 1 shows RSV-mediated weight changes and viral clearance in adult mice treated with intranasal IFNγ or PBS. Figs. 2–5 show changes in innate and adaptive immunity in RSV-infected adult mice treated with IFNγ or PBS.


#### 2. Experimental design, materials and methods

Balb/cJ mice aged 6–8 weeks, were ordered from The Jackson Laboratory, Bar Harbor, ME and were maintained in pathogen-free facilities in the Division of Laboratory Animal Resources at the University of Pittsburgh (Pittsburgh, PA). Experiments and animal handling were performed according to




**Fig. 3.** The expression of CD68 + macrophages (A-C), CD86 + CD68 + macrophages (D-F), and CD11c + MHCIIhi dendritic cells (G-I) are reported as percent of large cells in the BALF (A, D, G), total cells in the BALF (B, E, H), and total cells in digested whole lung tissue (C, F, I) following treatment with IFN $\gamma$  or PBS. Mean and SEM are reported with  $\geq 5$  mice per group; a one-way ANOVA describes group differences: \*p < 0.05; \*\*\*p < 0.001.

protocols approved by The University of Pittsburgh Institutional Animal Care and Use Committee. Where indicated, mice were infected intranasally (i.n.) with RSV Line 19 (RSV L19, Martin Moore, Emory University, Atlanta, GA) ( $5 \times 10^5$  pfu/g,  $\sim 1.5 \times 10^6$  pfu in 100 µl) under isoflurane anesthesia. On one day post infection (dpi) 50 µl of recombinant murine IFN $\gamma$  (16 ng/g) (Peprotech, Rocky Hill, NJ) or vehicle only (PBS) were delivered intranasally to RSV-infected mice under light isoflurane anesthesia on 1, 3, and 5 dpi. Mice were weighed daily; percent change from baseline weight was reported. At the indicated times post-infection, at least 5 mice per group were culled for tissue collection. Lungs were lavaged with HBSS-EDTA, then right lungs were harvested and processed for flow cytometry and left lungs were snap frozen for viral plaque assays as previously described [2].



**Fig. 4.** Total CD4 (A) and CD8 (C) T cells and total activated (CD69+) CD4 (B) and CD8 (D) T cells are reported for each group in digested lung tissue (lung) at 6 and 8 dpi in RSV-infected adult mice following treatment with intranasal IFN $\gamma$  or PBS. No significant differences were determined between groups using a one-way ANOVA.



**Fig. 5.** Total DX5 + NK cells (A) and activated (CD69+) NK cells (B) in digested lung tissue (lung) are reported in RSV-infected adult mice treated with intranasal IFN $\gamma$  or PBS. Mean and SEM are reported with  $\geq$  5 mice per group; a one-way ANOVA describes group differences: \*\*p < 0.01.

## Acknowledgements

**Funding:** This work was supported by the National Institutes of Health: T32 AI089443 (K Eichinger), R03 RHD080874A and KL2 RR024154-05 (K Empey), David and Betty Brenneman Fund (K Empey), and the University of Pittsburgh, Central Medical Research Fund (K Empey).

## Transparency document. Supporting information

Transparency data associated with this article can be found in the online version at http://dx.doi. org/10.1016/j.dib.2017.07.034.

#### References

- K.M. Eichinger, E. Resetar, J. Orend, K. Anderson, K.M. Empey, Age predicts cytokine kinetics and innate immune cell activation following intranasal delivery of IFNgamma and GM-CSF in a mouse model of RSV infection, Cytokine 97 (2017) 25–37.
- [2] K.M. Empey, J.G. Orend, R.S. Peebles Jr., L. Egana, K.A. Norris, T.D. Oury, J.K. Kolls, Stimulation of immature lung macrophages with intranasal interferon gamma in a novel neonatal mouse model of respiratory syncytial virus infection, PLoS One 7 (7) (2012) e40499.